NCT06929806View on ClinicalTrials.gov

Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure

PHASE3RecruitingINTERVENTIONAL
Enrollment

1,900

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2027

Conditions
Chronic Heart FailureIron Deficiencies
Interventions
DRUG

Ferric Derisomaltose

100 mg/mL

Trial Locations (1)

91105

RECRUITING

Private clinic, Pasadena

Sponsors

Lead Sponsor

Pharmacosmos A/S
All Listed Sponsors
lead

Pharmacosmos A/S

INDUSTRY

NCT06929806 - Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure | Biotech Hunter | Biotech Hunter